Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The prediction for Incyte Corp. disappointed with a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 3.207% | 3.207% | 74.975% | 82.995% |
| iShares Core DAX® | 0,85 % | 0,39 % | 2,53 % | 52,00 % |
| iShares Nasdaq 100 | -0,99 % | -4,40 % | 25,15 % | 77,54 % |
| iShares Nikkei 225® | -1,78 % | -11,22 % | 44,40 % | 64,68 % |
| iShares S&P 500 | 0,06 % | 0,78 % | 20,95 % | 63,01 % |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten